OBJECTIVE: To report the detection of secondary neurotransmitter abnormalities in a group of SPG11 patients and describe treatment with l-dopa/carbidopa and sapropterin. DESIGN: Case reports. SETTING: National Institutes of Health in the Undiagnosed Disease Program; Children's National Medical Center in the Myelin Disorders Bioregistry Program. PATIENTS: Four SPG11 patients with a clinical picture of progressive spastic paraparesis complicated by extrapyramidal symptoms and maculopathy. INTERVENTIONS: L-Dopa/carbidopa and sapropterin. RESULTS: 3/4 patients presented secondary neurotransmitter abnormalities; 4/4 partially responded to L-dopa as well as sapropterin. CONCLUSIONS: In the SPG11 patient with extrapyramidal symptoms, a trial of L-dopa/carbidopa and sapropterin and/or evaluation of cerebrospinal fluid neurotransmitters should be considered.
OBJECTIVE: To report the detection of secondary neurotransmitter abnormalities in a group of SPG11patients and describe treatment with l-dopa/carbidopa and sapropterin. DESIGN: Case reports. SETTING: National Institutes of Health in the Undiagnosed Disease Program; Children's National Medical Center in the Myelin Disorders Bioregistry Program. PATIENTS: Four SPG11patients with a clinical picture of progressive spastic paraparesis complicated by extrapyramidal symptoms and maculopathy. INTERVENTIONS:L-Dopa/carbidopa and sapropterin. RESULTS: 3/4 patients presented secondary neurotransmitter abnormalities; 4/4 partially responded to L-dopa as well as sapropterin. CONCLUSIONS: In the SPG11patient with extrapyramidal symptoms, a trial of L-dopa/carbidopa and sapropterin and/or evaluation of cerebrospinal fluid neurotransmitters should be considered.
Authors: L Samaranch; M Riverol; J C Masdeu; E Lorenzo; J M Vidal-Taboada; J Irigoyen; M A Pastor; P de Castro; P Pastor Journal: Neurology Date: 2008-07-29 Impact factor: 9.910
Authors: M Riverol; L Samaranch; B Pascual; P Pastor; J Irigoyen; M A Pastor; P de Castro; J C Masdeu Journal: J Neuroimaging Date: 2008-11-21 Impact factor: 2.486
Authors: Ute Hehr; Peter Bauer; Beate Winner; Rebecca Schule; Akguen Olmez; Wolfgang Koehler; Goekhan Uyanik; Anna Engel; Daniela Lenz; Andrea Seibel; Andreas Hehr; Sonja Ploetz; Josep Gamez; Arndt Rolfs; Joachim Weis; Thomas M Ringer; Michael Bonin; Gerhard Schuierer; Joerg Marienhagen; Ulrich Bogdahn; Bernhard H F Weber; Haluk Topaloglu; Ludger Schols; Olaf Riess; Juergen Winkler Journal: Ann Neurol Date: 2007-12 Impact factor: 10.422
Authors: Paola S Denora; David Schlesinger; Carlo Casali; Fernando Kok; Alessandra Tessa; Amir Boukhris; Hamid Azzedine; Maria Teresa Dotti; Claudio Bruno; Jeremy Truchetto; Roberta Biancheri; Estelle Fedirko; Maja Di Rocco; Clarissa Bueno; Alessandro Malandrini; Roberta Battini; Elisabeth Sickl; Maria Fulvia de Leva; Odile Boespflug-Tanguy; Gabriella Silvestri; Alessandro Simonati; Edith Said; Andreas Ferbert; Chiara Criscuolo; Karl Heinimann; Anna Modoni; Peter Weber; Silvia Palmeri; Martina Plasilova; Flavia Pauri; Denise Cassandrini; Carla Battisti; Antonella Pini; Michela Tosetti; Erwin Hauser; Marcella Masciullo; Roberto Di Fabio; Francesca Piccolo; Elodie Denis; Giovanni Cioni; Roberto Massa; Elvio Della Giustina; Olga Calabrese; Marina A B Melone; Giuseppe De Michele; Antonio Federico; Enrico Bertini; Alexandra Durr; Knut Brockmann; Marjo S van der Knaap; Mayana Zatz; Alessandro Filla; Alexis Brice; Giovanni Stevanin; Filippo M Santorelli Journal: Hum Mutat Date: 2009-03 Impact factor: 4.878
Authors: William A Gahl; John J Mulvihill; Camilo Toro; Thomas C Markello; Anastasia L Wise; Rachel B Ramoni; David R Adams; Cynthia J Tifft Journal: Mol Genet Metab Date: 2016-01-22 Impact factor: 4.797